NCT00977587View on ClinicalTrials.gov

Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

July 31, 2012

Conditions
Irritable Bowel SyndromePost Infective Bowel Dysfunction
Interventions
DRUG

Saccharomyces Cerevisiae CNCM I-3856

Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day

DRUG

placebo

"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"

Trial Locations (1)

NG7 2UH

Nottingham University Hospital, Nottingham

Sponsors

Collaborators (1)

Lesaffre International
All Listed Sponsors
collaborator

Lesaffre International

INDUSTRY

lead

University of Nottingham

OTHER

NCT00977587 - Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction | Biotech Hunter | Biotech Hunter